Bitvavo will stop trading Across Protocol (ACX) tokens on October 27, with deposits closing at 8 a.m. ET, trading ending at 9 a.m. ET, and withdrawals available until 10 a.m. ET that day. Holders have one hour after trading ends to withdraw ACX tokens to an external wallet or another exchange before Bitvavo closes support. Any ACX left on Bitvavo after the withdrawal deadline will be sold automatically and converted to euros by November 5. Across Protocol is transitioning to a private U.S. corporation, and ACX tokens will lose their governance and utility functions after January 8, 2027, when the portal options for token holders close. Token holders can exchange ACX for equity in Across, Inc. or redeem tokens for USDC through the portal before the deadline.
The Bitvavo announcement on ACX token trading and withdrawal deadlines provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 22, 2026 21:43 WIB: out of 50 priced major cryptocurrencies, 4 rose and 45 fell. Notable movers include AVAX at Rp165.990 with a 1-day change of -4.60% and typical hold time of 87 days, UNI at Rp128.653 down 4.23%, and ADA at Rp3.890 down 4.21%.
Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...
A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to support regula...
Nokia reported third-quarter 2026 earnings per share of $0.10, surpassing the $0.08 estimate, and revenue of $5.78 billion, exceeding the $5.72 billion forecast. The company's AI and cloud sales surged 123%, driven by high demand for its IP Networks ...
